Objective: The aim of this his study was to evaluate the real-world persistence, effectiveness, and safety of secukinumab in adult patients with moderate-to-severe psoriasis in two different hospitals.
Methods: Retrospective cohort study that used registries and medical records from 2 different hospitals (February 2015 to March 2024). Adults with moderate-to-severe psoriasis who initiated secukinumab treatment were identified and followed-up until March 2024, or disenrollment. Baseline demographic and clinical characteristics studied included sex, age at diagnóstico, weight, prior failed treatments, duration of treatment and psoriasis area severity index score (PASI). Adherence was measured using medication possession ratio (MPR); patients with MPR more than 80% were considered adherent. Persistence, effectiveness, safety, and dosage regimen of secukinumab were collected. Kaplan-Meier analysis was used to estimate secukinumab persistence using 1-year intervals.
Results: A total of 88 patients with moderate-to-severe psoriasis were included, of whom 45 (51.1%) had not received prior biological treatment. Baseline PASI score was 15.0 ± 2.9 and patients received 1.4 ± 0.8 prior biological treatments. The most common previous biological treatments included anti-TNFα (60.5%) and ustekinumab (20.9%). Thirty-four (38.6%) patients discontinued secukinumab treatment due to the following reasons. Nineteen (21.5%) due to a lack of effectiveness, 8 (9.2%), due to achieve only a partial response and 7 (7.9%) due to adverse effects. Secukinumab persistence was 61.5 ± 21.7 months for all patients. When performing a subgroup analysis, non-naïve patients obtained a persistence of 61.5 ± 12.4 months followed by 54.1 ± 14.8 months for naïve patients (p = 0.804). Secukinumab persistence at 1 year, 2 years and 3 years was 72.7, 51.1 and 39.8%, respectively.
Conclusions: Secukinumab demonstrated persistence in more than 70% of patients with moderate to severe psoriasis after the first year of treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.farma.2025.02.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Experience of Risankizumab in Patients With a History of Erythrodermic Psoriasis.
Exp Dermatol
March 2025
Department of Dermatology, College of Medicine, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan (ROC).
Erythrodermic psoriasis (EP) is a severe and challenging variant of psoriasis that often shows poor drug survival. While risankizumab, an IL-23 inhibitor, has demonstrated efficacy in patients with moderate-to-severe plaque psoriasis, its effectiveness in patients with a history of EP is less explored. This study aimed to evaluate treatment response to risankizumab and identify potential predictors influencing the treatment response.
View Article and Find Full Text PDFLong-term persistence with secukinumab in patients with moderate-to-severe psoriasis.
Farm Hosp
March 2025
Servicio de Farmacia, Hospital de Alzira, Valencia, España.
Objective: The aim of this his study was to evaluate the real-world persistence, effectiveness, and safety of secukinumab in adult patients with moderate-to-severe psoriasis in two different hospitals.
Methods: Retrospective cohort study that used registries and medical records from 2 different hospitals (February 2015 to March 2024). Adults with moderate-to-severe psoriasis who initiated secukinumab treatment were identified and followed-up until March 2024, or disenrollment.
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, was effective and well tolerated at a dose of 6 mg once daily through 1 year (52 weeks) in patients with moderate to severe plaque psoriasis in the phase 3 POETYK PSO-1 and POETYK PSO-4 trials. Patients completing PSO-1 or PSO-4 could enter the ongoing POETYK long-term extension trial and receive open-label deucravacitinib. Safety and efficacy were evaluated through 3 years (148 weeks; data cutoff date: June 15, 2022) in Japanese patients in these trials.
View Article and Find Full Text PDFA Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis.
Adv Ther
March 2025
Formycon AG, Fraunhoferstr. 15, 82152, Martinsried/Planegg, Germany.
Introduction: Biosimilars allow more patients access to affordable treatment options and help reduce the financial burden on healthcare systems. This multicentre trial compared the efficacy, safety, and immunogenicity of the approved biosimilar ustekinumab FYB202 with reference ustekinumab.
Methods: Eligible patients were ≥ 18 years old with stable moderate-to-severe plaque psoriasis for ≥ 6 months and inadequate treatment response to or intolerance of ≥ 1 previous systemic treatment.
Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.
Dermatol Ther (Heidelb)
March 2025
Alliance Clinical Trials and Probity Medical Research, Waterloo, ON, Canada.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!